Diligence memo · auto-generated · as of July 2, 2026
Genesis Biopharma, Inc
Genesis Biopharma, Inc looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Genesis Biopharma, Inc operates in Biotechnology, based in WOODLAND HILLS.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Genesis Biopharma, Inc has raised $132M in disclosed capital across 8 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $100M on 2016-06-02.
Most recent recorded round closed around 2016-06-02.
Valuation (modeled)modeled
Provath models Genesis Biopharma, Inc at approximately $4.1B (range $309M–$10.8B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.00× the median modeled value of Series C Biotechnology companies in 2016–2018 (41 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 10 months.
Last raise 10.1 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 4.3× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 93% of Biotechnology peers (4293 compared).
Modeled value ranks above 98% of those peers.
Closest niche peers: Alder Biopharmaceuticals Inc, Ideaya Biosciences, Inc., Stoke Therapeutics, Inc., 4D Molecular Therapeutics Inc, Sutro Biopharma Inc.
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.